DC-CIK免疫治疗对卵巢癌患者凝血功能及D-二聚体水平的影响

目的：探讨树突状细胞诱导的杀伤细胞（DC-CIK）免疫治疗前后卵巢癌患者凝血功能指标及D-二聚体水平的变化，并阐明其临床意义。方法：选择行DC-CIK治疗的40例卵巢癌患者，在粒细胞集落刺激因子（G-CSF）动员前5 d及DC-CIK免疫治疗1个月后行凝血功能各指标及D-二聚体水平的检测。比较卵巢癌患者DC-CIK免疫治疗前后凝血功能及D-二聚体水平的差异。结果：DC/CIK细胞回输后卵巢癌患者D-二聚体水平从1063μg·L^-1降至485μg·L^-1，纤维蛋白原（FIB）水平降低10%，DC/CIK治疗前后D-二聚体和FIB水平比较差异有统计学意义（P<0.05）。在Ⅳ期卵巢癌患者及>60岁卵巢癌患者中D-二聚体和FIB水平降低程度更为明显。与治疗前比较，治疗后D-二聚体水平正常（<243μg·L^-1）患者比例明显增加（P<0.05）。结论：DC-CIK免疫治疗可通过降低卵巢癌患者的D-二聚体及FIB水平，降低其静脉血栓风险。

Influence of DC-CIK immunotherapy in blood coagulation function and D-dimer levels in patients with ovarian cancer

Objective: To investigate the changes of blood coagulation function and D-dimer levels in the ovarian cancer patients before and after dentritic cells-cytokine-induced killer cells (DC-CIK) immunotherapy, and to clarify its clinical significance.Methods: Forty ovarian cancer patients treated with DC-CIK immunotherapy were selected. The indicators of blood coagulation function and the D-dimer levels. 5 d before G-CSF mobilization and 1 month after DC-CIK immunotherapy were detected. The differences in the blood coagulation function and D-dimer levels of the ovarian cancer patients were compared between before and after DC-CIK immunotherapy.Results: The D-dimer level of the ovarian cancer patients was decreased from 1063μg·L^-1 to 485μg·L^-1 after DC/CIK cell reinfusion (P<0.05), and the fibrinogen(FIB) level was decreased by 10%(P<0.05). The changes were more significant in the ovarian cancer patients at Ⅳstage (FIB) and the patients aged over 60 years old. Compared with before treatment,the proption of ovarian cancer patients with normal D-dimer level (<243μg·L^-1) after treatment was increased(P<0.05).Conclusion: DC-CIK immunotherapy can reduce the levels of D-dimer and FIB in the ovarian cancer patients, and also reduce the risk of venous thrombosis.